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Background & Aims: Genetic variations in proinflammatory
and anti-inflammatory cytokine genes influence individual
response to carcinogenic exposures. Polymorphisms in in-
terleukin (IL)-1 and its endogenous receptor antagonist
are associated with risk of Helicobacter pylori–related gas-
tric cancer. The aim of this study was to evaluate the role
of proinflammatory cytokine gene polymorphisms in gas-
tric and esophageal cancers defined by anatomic subsite.
Methods: We assessed polymorphisms of the IL-1 gene
cluster and 4 other cytokine genes in a population-based
case-control study of upper gastrointestinal cancers, in-
cluding gastric cardia (n  126) and noncardia adenocar-
cinoma (n  188), esophageal squamous cell carcinoma
(n  53), and adenocarcinoma (n  108), and frequency-
matched controls (n  212). ORs for the different cancers
were computed from logistic regression models adjusted
for potential confounding factors. Results: Proinflamma-
tory genotypes of tumor necrosis factor  and IL-10 were
each associated with more than doubling of the risk of
noncardia gastric cancer. Carriage of multiple proinflam-
matory polymorphisms of IL-1Bo IL-1 receptor antagonist,
tumor necrosis factor A, and IL-10 conferred greater risk,
with ORs (and 95% confidence intervals) of 2.8 (1.6–5.1)
for one, 5.4 (2.7–10.6) for 2, and 27.3 (7.4–99.8) for 3 or
4 high-risk genotypes. In contrast, these polymorphisms
were not consistently related to the risks of esophageal or
gastric cardia cancers. Polymorphisms in IL-4 and IL-6
were not associated with any of the cancers studied.
Conclusions: A proinflammatory cytokine genetic profile
increases the risk of noncardia gastric adenocarcinoma
but not other upper gastrointestinal cancers, possibly by
inducing a hypochlorhydric and atrophic response to gas-
tric H. pylori infection.
Cancers of the upper gastrointestinal tract are collec-tively the second most common type of cancer
worldwide1 and comprise 4 distinct entities: squamous
cell carcinoma of the esophagus, adenocarcinoma of the
esophagus, adenocarcinoma of the gastric cardia, and
adenocarcinoma of the distal (noncardia) stomach. The
available evidence for these tumors suggests that differ-
ent pathogenic mechanisms are involved. For example,
noncardia gastric adenocarcinoma occurs excessively in
patients with gastric atrophy and hypochlorhydria,2
which seem to protect against the more proximal cardia
and esophageal adenocarcinomas.3 Time trends also dif-
fer; the incidence rates for adenocarcinomas of the esoph-
agus and gastric cardia have increased steeply in indus-
trialized countries since the mid-1970s, while rates for
esophageal squamous cell carcinoma and noncardia gas-
tric adenocarcinoma have remained stable or decreased.4,5
The decline in incidence of noncardia gastric adenocar-
cinoma has paralleled the decreasing prevalence of infec-
tion with Helicobacter pylori, which plays an essential role
in initiating this cancer6 but could possibly protect
against the more proximal cancers.7,8
Host genetic factors are emerging as key determinants
of disease risk for many cancers.9,10 We recently reported
that functional polymorphisms in the genes for interleu-
kin 1 (IL-1B) and its endogenous receptor antagonist
(IL-1RN) were associated with increased risk of gastric
cancer and its precursors.11,12 These polymorphisms have
been shown to significantly affect gastric mucosal IL-1
production in response to H. pylori infection.13 The effect
of these polymorphisms is therefore most likely mediated
Abbreviations used in this paper: CI, confidence interval; IL, inter-
leukin; IL-1RN, interleukin-1 receptor antagonist; OR, odds ratio; TNF,
tumor necrosis factor.




through the higher production of IL-1, which is an
important proinflammatory cytokine and a powerful in-
hibitor of acid secretion.14 However, our initial study
only addressed gastric cancer, which consisted predomi-
nately of the noncardia gastric tumors.
The genetic control of inflammation may affect other
upper gastrointestinal cancers as well. Both proinflam-
matory and anti-inflammatory cytokine genes have rec-
ognized polymorphisms that alter gene transcription
and/or expression.15 In addition to the IL-1 gene cluster,
candidate genes include those encoding the proinflam-
matory cytokines tumor necrosis factor  (TNF-) and
IL-6, as well as the anti-inflammatory IL-4 and IL-10.
We therefore undertook a study to further investigate the
relationship between inflammatory cytokine polymor-




The subjects in this study came from a multicenter,
case-control study of esophageal and gastric cancer conducted
in 3 geographic areas of the United States with population-
based tumor registries.16 Population-based controls were fre-
quency matched by 5-year age group and sex, and were se-
lected by random-digit dialing and Health Care Financing
Administration roster sampling as previously described.16
Genomic DNA was obtained from peripheral blood samples
that had been collected at some of the participating centers17
or from paraffin-embedded tissue sections. DNA samples were
available for 161 subjects with esophageal cancer (53 with
squamous cell carcinoma and 108 with adenocarcinoma), 314
subjects with gastric adenocarcinoma (126 with cardia and 188
with noncardia adenocarcinomas), and 212 controls. H. pylori
serologic status was available on 214 subjects (46%) with
cancer and all controls as previously reported.17
Genotyping
We assessed a total of 7 single nucleotide polymor-
phisms in IL-1B (511 C/T), IL-4 (590 C/T), IL-6 (174
G/C), IL-10 (1082 G/A, 819 C/T, 592 C/A), and
TNF-A (308 G/A), as well as the variable number of tandem
repeat polymorphism of IL-1RN. Single nucleotide polymor-
phisms were discriminated by 5 nuclease polymerase chain
reaction assays (TaqMan) using methods as previously de-
scribed.11 The sequences of the primers and probes used in the
TaqMan assays are provided in Table 1 and were all developed
in our laboratory except for IL-4-590 (C/T), which was previ-
ously reported by Holloway et al.18
For the IL-1RN variable number of tandem repeat polymor-
phism, genomic DNA was polymerase chain reaction ampli-
fied and resultant products sized by gel electrophoresis as
previously described11; the rarer alleles 3 and 4 were grouped
in the statistical analysis.
Genotype data were complete for the IL-1B, IL1-RN, IL-10,
and TNF-A markers in all of the cases and in 210 controls; 2
control samples with degraded DNA could not be typed
completely and were excluded from analysis. The IL-4 and
IL-6 polymorphisms were only genotyped for subjects with
peripheral blood DNA because tissue DNA samples were
limited. For 27 subjects with DNA from both blood and tissue
samples, genotype results for the other 6 polymorphisms were
more than 99% identical in quality control analyses.
Statistical Analysis
Hardy–Weinberg equilibrium of alleles at individual
loci was assessed by 2 statistics. Odds ratios (OR) with
Cornfield 95% confidence intervals (CIs) were computed by
logistic regression using STATA version 7.0 software (STATA
Press, College Station, TX). ORs for the different cancers were
adjusted for age (categorized as younger than 50, 50–59,
60–69, and 70 years or older), sex, and race (categorized as
white and all other); alternative analyses stratified by race
provided similar estimates. Additional models were adjusted
for the effects of the genetic polymorphisms on one another,
Table 1. Sequences of Primers and Probes Used in the 5 Nuclease (TaqMan) Assays
Gene Primers Probes
IL-1B-511 F: 5-TCCTCAGAGGCTCCTGCAAT-3 FAM:TGTTCTCTGCCTCGGGAGCTCTCTG
C/T R: 5-TGTGGGTCTCTACCTTGGGTG-3 VIC:CTGTTCTCTGCCTCAGGAGCTCTCTGTC
IL-4-590 F: 5-CCTGTCCTTCTCAAAACACTAAACTTG-3 FAM:AACATTGTCCCCCAGTGCTGGG
C/T R: 5-GCAGAATAACAGGCAGACTCTCCTA-3 VIC:AGAACATTGTTCCCCAGTGCTGGG
IL-6-174 F: 5-CAATGACGACCTAAGCTGCACT-3 FAM:AGTTGTGTCTTGCGATGCTAAAGGACG
G/C R: 5-GCTGATTGGAAACCTTATTAAGATTGT-3 VIC:AGTTGTGTCTTGCCATGCTAAAGGACG
IL-10-1082 F: 5-CACACACACACAAATCCAAGACAA-3 FAM:AAGGCTTCTTTGGGAGGGGGAAGTAG
G/C R: 5-GCTGGATAGGAGGTCCCTTACTTT-3 VIC:AAGGCTTCTTTGGGAAGGGGAAGTAGG
IL-10-819 F: 5-GGGTGAGGAAACCAAATTCTCA-3 FAM:TACAGGTGATGTAACATCTCTGTGCCTCAG
C/T R: 5-CATGACCCCTACCGTCTCTATTTTA-3 VIC:TGTACAGGTGATGTAATATCTCTGTGCCTCAGT
IL-10-592 F: 5-GGTAAAGGAGCCTGGAACACATC-3 FAM:ACCCCGCCTGTCCTGTAGGAAGC
C/A R: 5-CCAAGCAGCCCTTCCATTT-3 VIC:ACCCCGCCTGTACTGTAGGAAGC
TNF-A-308 F: 5-CCCCAAAAGAAATGGAGGC-3 FAM:AGGGGCATGGGGACGGG
G/A R: 5-TCTTCTGGGCCACTGACTGAT-3 VIC:TGAGGGGCATGAGGACGGG
F, forward primer; R, reverse primer; FAM, wild-type allele; VIC, mutant allele.
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histologic subtype (Lauren classification), cigarette smoking
(categorized as current, former, and never), alcohol consump-
tion (categorized as greater or less than one drink per month),
history of gastroesophageal reflux disease,19 body mass index
(in quartiles), history of gastric or duodenal ulcer disease, H.
pylori serologic status,17 and family history of esophageal or
gastric cancer. Population-attributable fractions of the various
cancers were estimated from logistic regression models com-
paring subjects with one or more polymorphisms to subjects
with none.
The study was approved by the institutional review boards
of the participating centers, and written informed consent was
obtained from all subjects.
Results
Demographic and risk-factor characteristics of the
subjects with cancer and the controls (Table 2) were
similar to those reported in the previous study.16
Among controls, the alleles at all of the individual loci
studied were in Hardy–Weinberg equilibrium, with
nominally nonsignificant 2 values (Table 3). Neverthe-
less, only 9 (4%) had the homozygous variant genotype
of IL-1B-511, whereas 16 (7%) were expected based on
allele frequencies (Hardy–Weinberg 2  5.6; P  0.07,
2 df ). Based on genotype frequencies reported from other
white populations, the paucity of IL-1B-511T/T among
the controls was an anomaly that had the effect of exag-
gerating the case-control comparisons for this genotype.
In all subjects, there was 100% linkage disequilibrium
between the IL-10-819 and -592 alleles as previously
reported.20,21
Associations With Polymorphisms in the
IL-1 Gene Cluster
Carriers of the proinflammatory IL-1B-511T al-
lele had a significantly increased risk of noncardia gastric
cancer; the association seemed to be greater in homozy-
gotes than in heterozygotes due to the low frequency of
homozygous controls (Table 4). In a logistic regression
model that included the other genetic markers, the ad-
justed OR for IL-1B-511T carriers (homozygotes and
heterozygotes) was 2.3 (95% CI, 1.4–3.8). Although
homozygotes also had statistically significant excess
risks of the other 3 cancers, these increases may have
been artifactual because there were no increases in risk
for heterozygotes or for IL-1B-511T carriers overall
(Table 5).
Additionally, IL-1RN*2 was associated with an in-
creased risk of both noncardia gastric cancer and esoph-
ageal squamous cell cancer but only in homozygotes,
with adjusted ORs of 3.6 (95% CI, 1.7–7.6) and 4.2
(95% CI, 1.3–13.9), respectively (Table 5). Carriers of
the rarer IL-1RN alleles 3 or 4 had an increased risk of
esophageal adenocarcinoma of marginal statistical signif-
icance (P  0.03).
Table 2. Selected Characteristics of Patients With Different Types of Upper Gastrointestinal Cancer and Controls
Characteristic












Age (median years) 66 65 66 70 66
Sex (% male) 89 86 87 77 85
Race (% white) 75 97 97 85 94
Body mass index (median kg/m2) 24.3 26.6 25.8 25.1 25.3
Cigarette Users (%)
Current 47 32 33 27 24
Former 43 47 47 48 45
Alcohol (% regular users) 98 76 80 70 85
History of reflux symptoms (%) 21 61 40 38 30
History of peptic ulcer (%)
Gastric 13 11 10 19 7
Duodenal 4 10 9 12 6
Family history of cancer (%)
Esophageal 0 2 2 2 2
Gastric 8 8 8 14 4
Lauren classification (%)
Diffuse (%) — 14 24 47 —
Intestinal (%) — 73 59 34 —
H. pylori immunoglobulin G antibody (% positive) 58 32 26 48 40
DNA source (% peripheral blood) 45 61 46 35 100
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Associations With Polymorphisms in Other
Proinflammatory Cytokine Genes
Carriers of the proinflammatory TNF-A-308A al-
lele had a significantly increased risk of noncardia gastric
cancer that was more pronounced for homozygotes than
heterozygotes. Adjusted for the effects of the other ge-
netic markers, the OR for TNF-A-308A was 2.2 (95%
CI, 1.4–3.7). TNF-A-308A carriers were not at in-
creased risk for the other gastrointestinal cancers (Table
5). No statistically significant associations of IL-6-174C
were seen for any of the 4 cancers.
Associations With Polymorphisms in
Anti-inflammatory Cytokine Genes
Subjects homozygous for the hypoactive IL-10
alleles IL-10-1082A and IL-10-592A, as well as for the
“low IL-10” haplotype ATA (IL-10-1082A, IL-10-819T,
and IL-10-592A)21 had significantly increased risks of
noncardia gastric cancer. Compared with homozygotes
for the “high IL-10” haplotype GCC, the adjusted OR
for low IL-10 homozygotes was 2.5 (95% CI, 1.1–5.7).
The low IL-10 haplotype was not associated with risk for
the other cancers (Table 5). Homozygotes for the IL-4-
590T allele were not at altered risk for any of the cancers,
although heterozygotes had an excess of esophageal squa-
mous cell cancer of marginal statistical significance (P 
0.02; Table 4).
Association With Composite of Cytokine
Polymorphisms
To analyze the combined association with in-
creases in proinflammatory cytokines and decreases in
Table 3. Cytokine Genotype Frequencies in Patients With Different Types of Upper Gastrointestinal Cancer and Controls
Genotype













C/C 21 (40) 50 (46) 57 (45) 47 (25) 104 (50)
C/T 21 (40) 46 (43) 56 (44) 98 (52) 97 (46)
T/T 11 (20) 12 (11) 13 (11) 43 (23) 9 (4)
IL-1RN
1/1 30 (57) 49 (46) 69 (55) 81 (43) 114 (55)
1/2 12 (23) 40 (37) 42 (33) 59 (31) 76 (36)
1/3,4 2 (3) 10 (9) 3 (2) 2 (1) 7 (3)
2/2 8 (15) 8 (7) 12 (10) 45 (24) 13 (6)
2/3 1 (2) 1 (1) 0 (0) 1 (1) 0 (0)
IL-4-590
G/G 11 (46) 44 (67) 41 (71) 37 (58) 153 (73)
G/T 11 (46) 17 (26) 16 (27) 21 (33) 46 (22)
T/T 2 (8) 5 (7) 1 (2) 6 (9) 10 (5)
IL-6-174
G/G 13 (54) 20 (30) 22 (38) 33 (51) 83 (40)
G/C 6 (25) 33 (50) 31 (53) 21 (32) 98 (47)
C/C 5 (21) 13 (20) 5 (9) 11 (17) 28 (13)
IL-10-1082
G/G 9 (17) 23 (21) 30 (24) 31 (16) 48 (23)
G/A 28 (53) 59 (55) 62 (49) 71 (38) 103 (49)
A/A 16 (30) 26 (24) 34 (27) 86 (46) 59 (28)
IL-10-592
C/C 35 (66) 72 (67) 80 (64) 98 (52) 127 (61)
C/A 15 (28) 29 (27) 38 (30) 63 (34) 70 (33)
A/A 3 (6) 7 (6) 8 (6) 27 (14) 13 (6)
IL-10
GCC/
GCC 8 (15) 23 (21) 30 (24) 31 (16) 48 (23)
Othera 43 (81) 79 (73) 88 (70) 131 (70) 150 (71)
ATA/ATA 2 (4) 6 (6) 8 (6) 26 (14) 12 (6)
TNF-A-308
G/G 41 (77) 81 (75) 91 (72) 110 (59) 152 (72)
G/A 10 (19) 24 (22) 30 (24) 57 (30) 52 (25)
A/A 2 (4) 3 (3) 5 (4) 21 (11) 6 (3)
aIL-10 genotypes other than GCC/GCC or ATA/ATA.
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anti-inflammatory cytokines, subjects were classified ac-
cording to their number of inflammation-promoting cy-
tokine polymorphisms, defined as follows: (1) carriage of
IL-1B-511T, (2) homozygosity for IL-1RN*2, (3) car-
riage of TNF-A-308A, and (4) homozygosity for the low
IL-10 haplotype ATA. The OR for noncardia gastric
cancer increased progressively with increasing number of
proinflammatory genotypes to 27.3 (95% CI, 7.4–99.8;
Table 6) for 3 or 4 polymorphisms. In contrast, the
number of proinflammatory cytokine polymorphisms did
not significantly affect the risk of esophageal squamous
cell carcinoma, adenocarcinoma, or gastric cardia cancer,
Table 4. Age-, Sex-, and Race-Adjusted ORs (and Cornfield 95% CIs) for the Association of Cytokine Gene Polymorphisms
With Different Types of Upper Gastrointestinal Cancer
Genotype











C/C 1.0 1.0 1.0 1.0
C/T 0.9 (0.5–1.9) 1.0 (0.6–1.6) 1.1 (0.7–1.8) 2.4 (1.5–3.8)
T/T 6.6 (2.2–19.8) 2.93 (1.1–7.7) 3.1 (1.2–8.0) 9.5 (4.0–22.7)
IL-1RN
1/1 1.0 1.0 1.0 1.0
1/2 0.7 (0.3–1.6) 1.2 (0.7–2.0) 0.9 (0.5–1.4) 1.2 (0.7–1.9)
1/3,4 2.1 (0.4–12.0) 3.3 (1.1–9.5) 0.7 (0.2–2.9) 0.8 (0.2–4.0)
2/2 3.3 (1.2–9.2) 1.3 (0.5–3.5) 1.6 (0.7–3.7) 5.4 (2.6–11.1)
IL-4-590
G/G 1.0 1.0 1.0 1.0
G/T 3.2 (1.2–8.3) 1.4 (0.7–2.7) 1.4 (0.7–2.9) 1.8 (0.9–3.5)
T/T 1.7 (0.2–14.2) 2.0 (0.5–7.6) 0.6 (0.1–4.9) 1.4 (0.3–5.9)
IL-6-174
G/G 1.0 1.0 1.0 1.0
G/C 0.5 (0.2–1.5) 1.4 (0.8–2.8) 1.1 (0.6–2.1) 0.7 (0.3–1.3)
C/C 1.2 (0.4–4.1) 1.9 (0.8–4.4) 0.6 (0.2–1.8) 1.3 (0.5–3.1)
IL-10-1082
G/G 1.0 1.0 1.0 1.0
G/A 1.3 (0.5–3.0) 1.2 (0.7–2.2) 1.0 (0.6–1.8) 1.0 (0.6–1.8)
A/A 1.1 (0.4–2.9) 0.8 (0.4–1.7) 1.1 (0.6–2.1) 1.9 (1.1–3.5)
IL-10-592
C/C 1.0 1.0 1.0 1.0
C/A 0.6 (0.3–1.2) 0.8 (0.5–1.3) 0.9 (0.6–1.5) 1.2 (0.8–1.9)
A/A 0.3 (0.1–1.4) 1.3 (0.5–3.8) 1.4 (0.5–3.9) 2.4 (1.1–5.1)
IL-10
GCC/GCC 1.0 1.0 1.0 1.0
Othera 1.5 (0.7–3.6) 1.1 (0.6–1.9) 1.0 (0.6–1.7) 1.2 (0.7–2.1)
ATA/ATA 1.0 (0.1–6.0) 1.2 (0.3–4.3) 1.7 (0.5–6.1) 3.4 (1.3–8.8)
TNF-A-308
G/G 1.0 1.0 1.0 1.0
G/A 0.8 (0.4–1.7) 0.9 (0.5–1.6) 1.0 (0.6–1.6) 1.5 (0.9–2.4)
A/A 1.3 (0.2–6.9) 1.2 (0.3–5.3) 1.5 (0.4–5.0) 4.8 (1.8–12.8)
aIL-10 genotypes other than GCC/GCC or ATA/ATA.
Table 5. Multivariate Model–Estimated ORs (and Cornfield 95% CIs) for the Association of Proinflammatory Genotypes With
Different Types of Upper Gastrointestinal Cancer
Genotype










IL-1B-511T 0.9 (0.4—2.0) 1.0 (0.6–1.7) 1.2 (0.7–1.9) 2.3 (1.4–3.8)
IL-1RN*2/*2 4.2 (1.3–13.9) 1.0 (0.4–2.8) 1.4 (0.6–3.3) 3.6 (1.7–7.6)
IL-10 ATA/ATA 0.3 (0.1–2.1) 1.5 (0.5–4.4) 1.3 (0.5–3.6) 2.5 (1.1–5.7)
TNF-A-308A 0.8 (0.4–1.7) 1.0 (0.6–1.8) 1.1 (0.6–1.8) 2.2 (1.4–3.7)
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with ORs for carriage of 3 or 4 proinflammatory geno-
types of 0 (95% CI, 0–10.5), 1.3 (95% CI, 0.2–8.0), and
3.6 (95% CI, 0.8–16.7), respectively.
Sixteen percent of the subjects with noncardia gastric
cancer but only 2% of the controls had 3 or 4 high-risk
genotypes, whereas 37% of the controls compared with
12% of the subjects with noncardia gastric cancer had no
high-risk genotypes. Assuming these associations are
causal, the combined population-attributable fraction of
noncardia gastric cancer due to the effect of these alleles
is estimated to be 67%.
Similar results were obtained after exclusion of sub-
jects with DNA from tumor specimens and in separate
analyses for each histologic subtype defined by Lauren
classification. The estimated effects of the proinflamma-
tory genotypes were not altered substantially after ad-
justment for the effects of possible confounders of the
risk of noncardia gastric cancer (data not shown).
Effects of Cytokine Polymorphisms
in H. pylori–Seropositive Subjects
Less than half of the subjects with cancer had
blood available for H. pylori serologic analysis. Among
those with H. pylori seropositivity, the OR estimates for
noncardia gastric cancer were 4.2 for IL-1B-511*T, 1.6
for IL-1RN*2*2, 2.9 for IL-10 ATA/ATA, and 2.9 for
TNF-A-308*2. For those with CagA-positive serology,
the OR estimates were higher (9.9, 2.9, 5.2, and 6.2 for
the above markers, respectively). For the composite esti-
mates, the H. pylori–seropositive and CagA-seropositive
subjects had OR estimates of 5.4 and 6.6 for one marker,
8.3 and 19.5 for 2 markers, and 42.0 and undefined for
3 markers, respectively. H. pylori serologic markers did
not apparently affect the OR estimates for the other
upper gastrointestinal cancers.
Discussion
We have identified a proinflammatory profile of
genetic polymorphisms in IL-1B, IL-1RN, IL-10, and
TNF-A associated with an increased risk of gastric cancer
that was limited to noncardia tumors. No associations
were seen with cancers of the gastric cardia or esophagus.
The IL-1 gene cluster polymorphisms were associated
with gastric cancer in 2 previous reports.11,22 The ORs
are similar in all 3 studies (all in predominantly white
populations), underscoring the central role of IL-1 in
the pathogenesis of H. pylori–associated gastric cancer. A
novel finding in our study is the identification of the
proinflammatory genotypes of TNF-A and IL-10 as ad-
ditional risk factors.
TNF- is up-regulated early in H. pylori coloniza-
tion and induces the transcription of a wide range of
other proinflammatory cytokines and chemokines, am-
plifying the inflammatory cascade against the infec-
tion.23 Although not as potent as IL-1, TNF- also
inhibits gastric acid secretion,24 which paradoxically
promotes spread of the organism. The association with
the low IL-10 haplotype may be related to the role of
IL-10 as an anti-inflammatory cytokine that down-
regulates IL-1, TNF-, interferon gamma, and other
proinflammatory cytokines. Relative deficiency of
IL-10 may result in a Th-1– driven hyperinflammatory
response to H. pylori with greater damage to the
gastric mucosa.25–28 Imbalances among proinflamma-
tory and anti-inflammatory mediators and acid pro-
duction may favor the development of gastric atrophy
and its progression to cancer.
The association of these polymorphisms with gastric
cancer requires the presence of H. pylori and may be most
important early in the disease process. When H. pylori
infects gastric mucosa, it induces a vigorous inflamma-
tory response with high levels of IL-1 and TNF-. The
direct effects of these cytokines are advantageous to
eradication of H. pylori organisms, but the concomitant
inhibition of acid secretion may extend the area of col-
onization affecting the corpus mucosa, which is other-
wise protected by an acidic environment. The critical
role of acid in determining the pattern of gastritis is well
shown by the changes resulting from its pharmacologic
inhibition. H. pylori–infected patients on long-term pro-
ton pump inhibitor therapy may experience an exacer-
bation of gastritis, with a shift to corpus predominance
and an increased risk of gastric atrophy.29
In addition, a decreased flow of gastric secretions may
promote accumulation of the genotoxic by-products of
inflammation, causing more mucosal damage and an
increased rate of mutation. As the inflammatory process
extends across the corpus, the acid secretion is further
inhibited in a continuing cycle that accelerates glandular
loss and onset of gastric atrophy. The hypochlorhydric
Table 6. Frequencies and Age-, Sex-, and Race-Adjusted
ORs (and Cornfield 95% CIs) for the Association
of 1–4 Proinflammatory Polymorphisms in IL-1B,






(n  210) OR (95% CI)
0 22 75 (Referent)
1 74 85 2.8 (1.6–5.1)
2 62 46 5.4 (2.7–10.6)
3 28 4 26.3 (7.1–97.1)
4 2 0  (Undefined)
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milieu also promotes growth of non–H. pylori bacteria,
which may contribute to mucosal damage and/or pro-
duction of carcinogenic N-nitrosocompounds.30 With
progression from mild gastritis through severe gastritis,
atrophy, and intestinal metaplasia, it becomes more dif-
ficult for H. pylori to colonize and be detected.31
While H. pylori infection and host genetics interact to
initiate a hypochlorhydric and atrophic phenotype, other
factors may contribute to subsequent neoplastic transfor-
mation, which does not depend on continued presence of
the infection. Diet may be particularly relevant, because
greater consumption of fresh fruits and vegetables has
been shown to protect against the risk of gastric cancer.
In particular, dietary vitamin C reduces the formation of
N-nitrosocompounds and scavenges mutagenic reactive
oxygen metabolites generated by gastric inflammation,32
and supplemental vitamin C was associated with a sig-
nificantly lower risk of noncardia gastric cancer in this
study population33; furthermore, vitamin C concentra-
tions and bioavailability are reduced in the presence of H.
pylori infection.34,35 Another factor for transformation is
cigarette smoking, which was found to nearly double the
risk of transition from atrophic gastritis to dysplasia in a
high-risk population.36 Thus, cytokine gene polymor-
phisms represent one component of a complex interplay
among the host, pathogen, and environmental factors
involved in gastric carcinogenesis.
In the present study, we did not have an opportunity
to fully assess the interaction between host genetic fac-
tors and H. pylori virulence factors, because gastric biopsy
material for isolation of H. pylori strains was not avail-
able. Our limited analysis using the subgroup of subjects
with serologic data showed a strong effect of the proin-
flammatory cytokine gene polymorphisms in the pres-
ence of CagA seropositivity. Our data thus concur with
the recent report by Figueiredo et al.37 that the risk of
gastric cancer is greatest in subjects with both bacterial
and host high-risk genotypes.
Notably, the proinflammatory cytokine profile did not
affect the risk of the other upper gastrointestinal tract
cancers. Esophageal adenocarcinoma is believed to arise
from Barrett’s esophagus, a precancerous metaplasia in-
duced by chronic gastroesophageal reflux of acidic gastric
contents.38–40 Theoretically, H. pylori–induced gastritis
and secondary hypochlorhydria reduce the amount of
acid production and refluxate. Accordingly, it has been
argued that H. pylori colonization,41 particularly with the
CagA-positive strains, may be protective against gastro-
esophageal reflux disease and its complications, such
as Barrett’s esophagus, dysplasia, and adenocar-
cinoma.7,17,42,43 It might be expected that proinflamma-
tory genotypes enhancing gastric acid inhibition would
be protective against esophageal and possibly gastric
cardia adenocarcinoma, but our data do not provide
support for this hypothesis.
Our study also showed that homozygous carriage of
the proinflammatory allele of IL-1RN was associated
with risk of esophageal squamous cell carcinoma.
However, risk was not related to the other proinflam-
matory markers associated with response to H. pylori,
suggesting differences in the cytokine repertoire pre-
disposing to the distinctive etiologic factors for esoph-
ageal squamous cell cancer, including alcohol, smok-
ing, and nutritional deficiency. The associations we
observed with IL-1RN and IL-4 polymorphisms war-
rant further investigation in larger studies of esopha-
geal cancer.
Although required for inclusion in this study, DNA
collection was unlikely to have been influenced by cyto-
kine genotype and therefore should not have biased our
results. The absence of selection or survival bias was
further supported by the similarity in genotyping find-
ings based on subjects with DNA from blood or from
tumor tissue. In addition, there was no evidence that
DNA availability for the present study was associated
with demographic or risk-factor characteristics previ-
ously reported for these populations.16
In conclusion, our findings indicate that a proinflam-
matory host genotype favors the development of a hypo-
chlorhydric, atrophic response to gastric infection with
H. pylori, which in turn predisposes to noncardia gastric
adenocarcinoma but not to cardia or esophageal cancers.
Pathophysiologic considerations indicate that cytokine
dysregulation is important in initiating this disease pro-
cess, but the multistep progression from atrophy to
neoplastic transformation depends on other factors, in-
cluding diet and tobacco. Better understanding of the
risk factors involved in the early and late stages of gastric
carcinogenesis should enhance the prospects for preven-
tive and therapeutic interventions.
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